Page last updated: 2024-12-11

fk 409

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

FK 409: structure given in first source; from Streptomyces griseoporeus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6413529
CHEMBL ID125865
SCHEMBL ID4806548
SCHEMBL ID961825
MeSH IDM0171464

Synonyms (24)

Synonym
(e,2z)-4-ethyl-2-hydroxyimino-5-nitro-hex-3-enamide
fr-900409
fk-409
brn 5943134
4-ethyl-2-(hydroxyimino)-5-nitro-3-hexenamide (?,e)-
3-hexenamide, 4-ethyl-2-(hydroxyimino)-5-nitro-, (?,e)-
(+/-)-(e)-ethyl-2-[(e)-hydroxyimino]-5-nitro-3-hexeneamide
fk 409
nor-3
fk409
CHEMBL125865
nor-3 cpd
92454-60-9
nor3 hexenamide cpd
4-ethyl-2-hydroxyimino-5-nitro-3-hexenecarboxamide
ethyl-2-(hydroxyamino)-5-nitro-3-hexenamide
4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide
SCHEMBL4806548
SCHEMBL961825
(2e,3e)-4-ethyl-2-(hydroxyimino)-5-nitro-3-hexenamide
(+/-)-(e)-4-ethyl-2-[(e)-hydroxyimino]-5-nitro-3-hexenamide
J-010013
nor3
(2e,3e)-4-ethyl-2-(hydroxyimino)-5-nitrohex-3-enamide

Research Excerpts

Overview

FK 409 is an orally active vasodilator with a hemodynamic profile similar to that of NTG.

ExcerptReferenceRelevance
"FK 409 is an orally active vasodilator with a hemodynamic profile similar to that of NTG."( Coronary and systemic hemodynamic effects of the putative nitric oxide donor, FK 409, in comparison with nitroglycerin in conscious and anesthetized dogs.
Drieu la Rochelle, C; Grosset, A; Lainée, P; O'Connor, SE, 1995
)
1.24

Toxicity

ExcerptReferenceRelevance
"We compared the gastric toxic effect of aspirin (ASA) in both normal and diabetic rats, with that of NCX-4016, a derivative of ASA with nitric oxide (NO) releasing moiety."( Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats.
Fujita, A; Takeuchi, K; Tashima, K; Umeda, M, 2000
)
0.31
"The gastric toxic effects of aspirin (ASA) and NCX-4016, a nitric oxide (NO)-releasing ASA, were compared in normal, cirrhotic, and arthritic rats."( Low gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in rats with cirrhosis and arthritis.
Kato, S; Komoike, Y; Suzuki, K; Takeuchi, K; Ukawa, H, 2001
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
" We measured in vivo pharmacokinetic parameters of antipyrine in rats treated with endotoxin and/or a selective inhibitor of inducible NO synthase (iNOS), S-methylisothiourea."( Decreased antipyrine clearance following endotoxin administration: in vivo evidence of the role of nitric oxide.
Hasegawa, T; Iwase, M; Kitaichi, K; Nadai, M; Shibata, E; Takagi, K; Wang, L, 1999
)
0.3

Dosage Studied

ExcerptRelevanceReference
" It shifted the dose-response curve of morphine to the left."( The interaction of FK409, a novel nitric oxide releaser, and peripherally administered morphine during experimental inflammation.
Nozaki-Taguchi, N; Yamamoto, T, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID513571Induction of S-nitrosylation of TRPC5 in HEK cells assessed as increase in Ca2+ level from extracellular space at 5 mM2006Nature chemical biology, Nov, Volume: 2, Issue:11
Nitric oxide activates TRP channels by cysteine S-nitrosylation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (138)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (2.90)18.7374
1990's53 (38.41)18.2507
2000's70 (50.72)29.6817
2010's11 (7.97)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.11 (24.57)
Research Supply Index4.99 (2.92)
Research Growth Index5.73 (4.65)
Search Engine Demand Index17.79 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.68%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other145 (99.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]